A Phase 2 Open-label Multicenter Study of an Immunotherapeutic Treatment DPX-Survivac in combination with Low Dose Cyclophosphamide and Pembrolizumab in Subjects with Selected Advanced and Recurrent Solid Tumours.

Brief description of study

In this study, we are trying to determine the safety and ability of an investigational product, called DPX Survivac, to help the immune system fight selected advanced and recurrent solid tumours. The purpose of this study is to test whether this combination of drugs will shrink or slow the growth or eliminate the tumour in the participants. While testing this we will also learn about the safety of the treatment and how the immune system responds.


Clinical Study Identifier: s18-02086
ClinicalTrials.gov Identifier: NCT03836352
Principal Investigator: Eva Chalas-Westermann.


Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.